Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lindsey Grady

Physician Assistant, Medical Valparaiso, IN Physician Assistant

NPI 1689954828 CMS profile 11066149

1703 Calumet Ave, Valparaiso, IN 46383

Open in the dashboard

General payments

$38,716

703 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lindsey Grady of Valparaiso, IN is reported in the CMS Open Payments database as having received $38,716 across 703 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19,235 206
2024 General $4,698 139
2023 General $11,878 176
2022 General $1,954 125
2021 General $952 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lindsey Grady
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Lindsey Grady were reported at $19,235. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Lindsey Grady Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $952 $156 $41–$563 $132
2022 $1,954 $185 $55–$649 $149
2023 $11,878 $199 $58–$717 $160
2024 $4,698 $206 $62–$740 $164
2025 $19,235 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $23,605 85 payments
  2. Arcutis Biotherapeutics, Inc. $4,800 16 payments
  3. AbbVie, Inc. $2,181 169 payments
  4. Sun Pharmaceutical Industries Inc. $1,147 57 payments
  5. Lilly USA, LLC $962 60 payments
  6. Dermavant Sciences, Inc. $743 36 payments
  7. UCB, Inc. $715 32 payments
  8. Novartis Pharmaceuticals Corporation $708 31 payments
  9. Janssen Biotech, Inc. $606 27 payments
  10. Incyte Corporation $589 31 payments
  11. Other $2,661 159 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,800 17 payments
  2. Food and Beverage $12,336 663 payments
  3. Travel and Lodging $5,069 17 payments
  4. Consulting Fee $3,125 1 payment
  5. Education $386 5 payments
Products named General payments · program years 2021–2025
  1. Otezla $22,980 84 payments
  2. SKYRIZI $1,254 106 payments
  3. ILUMYA $859 52 payments
  4. VTAMA $785 43 payments
  5. TALTZ $628 49 payments
  6. RINVOQ $594 31 payments
  7. OPZELURA $589 31 payments
  8. TREMFYA $546 24 payments
  9. Bimzelx $528 25 payments
  10. DUPIXENT $388 15 payments
  11. Other $4,831 273 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,117

Median for Physician Assistant: 241

Drug cost

$441,912

Median for Physician Assistant: $4,110

Branded share of claims

11.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 59 $218,219
Otezla Apremilast Brand 24 $115,253
Taltz Autoinjector Ixekizumab Brand 13 $85,991
Metronidazole Generic 59 $4,259
Clobetasol Propionate Generic 77 $3,300
Ketoconazole Generic 244 $3,061
Tacrolimus Generic 19 $2,442
Doxycycline Hyclate Generic 71 $1,716
Triamcinolone Acetonide Generic 170 $1,633
Betamethasone Dipropionate Generic 38 $1,136

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$159,487

Of which drugs: $4,686

Medicare patients

849

Average age 73

Services billed

4,738

490 women, 359 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 43%
Ischemic heart disease 23%
Diabetes 22%
Chronic kidney disease 15%
Cancer 15%
Atrial fibrillation 14%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 58 $43

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Otezla
  • Amgen Inc. $2,368
$2,368 24 —
SKYRIZI
  • AbbVie, Inc. $519
$519 — —
VTAMA
  • Dermavant Sciences, Inc. $514
$514 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $215
$215 — —
OPZELURA
  • Incyte Corporation $204
$204 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

703 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record